NCT01013272

Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: The University of Hong Kong · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Patients with chronic hepatitis B and treated with entecavir for over 6 months (with no previous other antiviral treatment) will be invited to participate in this study. They will be eligible if their liver tests are normal and their viral load is undetectable. Patients will be switched to lamivudine treatment to assess whether lamivudine can maintain adequate suppression of the hepatitis B virus after successful treatment with entecavir. Patients will be monitored closely after switching treatment at 1 months and then every 3 monthly. If there is any evidence of increase in viral load then patients will be given the option of changing back to entecavir.

Conditions

• Hepatitis B, Chronic

Interventions

Type	Name	Description
DRUG	Entecavir	Entecavir 0.5mg orally daily
DRUG	Lamivudine	Lamivudine 100mg orally, daily

Timeline

• Start date: 2007-06-01
• Primary completion: 2010-07-01
• Completion: 2010-07-01
• First posted: 2009-11-13
• Last updated: 2015-12-02

Locations

1 site across 1 country: China